Advice
following a full submission:
adalimumab (Humira) is accepted for restricted use within NHS Scotland for the treatment of rheumatoid arthritis (RA).
It should be initiated only by specialist physicians experienced in the diagnosis and treatment of RA, and used in accordance with British Society Rheumatology (BSR) guidelines for prescribing TNF-blockers in adults [which have been endorsed by the National Institute of Clinical Excellence (NICE) and QIS]. The BSR have established a Biologics Registry and details of patients treated with TNF-antagonists including adalimumab should be entered into this database. Adalimumab is the third TNF-antagonist licensed for the treatment rheumatoid arthritis (RA).
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- adalimumab (Humira)
- SMC ID:
- 81/03
- Indication:
Rheumatoid arthritis
- Pharmaceutical company
- Abbott Laboratories
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 08 December 2003